Customer-focused event will demonstrate achievement of improved EM
WALKERSVILLE, Md., Thursday, November 18th 2010 [ME NewsWire]:
(BUSINESS WIRE)-- Lonza will offer a live Webinar on the benefits and value of implementing LabVantage Micro/EM™, powered by MODA™—a paperless QC Micro solution by Lonza—on Tuesday, December 14, 2010 at 8:00 AM EST (International) or 11:00 AM EST (US).
The presentation will feature Karen Grohalski, Manager of Laboratory Operations, Quality Systems at Pfizer Global Manufacturing, the world’s leading biopharmaceutical company with a diversified global health care portfolio. Also presenting will be Robert Voelkner, from LabVantage Solutions, a co-sponsor of the event.
Webinar topics will include:
- LabVantage® and Lonza Vision to Integrate MODA™ Solution with LIMS
- Pfizer's Rationale to Augment LIMS with Purpose-built QC Micro Solution
- Pfizer's Previous Processes; Need for Automation and Integration with LIMS
- Pfizer's New Automated QC Micro Program
- Why Pfizer Selected LabVantage Micro/EM™, powered by MODA™
- Pfizer’s Plans for the Future
This webinar will discuss QC automation best practices that Pfizer is implementing across some of its global manufacturing facilities, and the functionality gap between standalone LIMS and today’s requirements in QC Micro for EM, utility, and product testing. Topics will be relevant to IT and business audiences.
To register, visit http://www.tmecom.com/lonza/webinars/121410/registration.html
Paper-based processes still burden most QC Micro programs: paper scheduling, sharpie pen labeling of sample media, manual reconciliation, paper log book entry, and manual notification on deviations. These steps are labor-intensive, time consuming, and yield duplication of tasks and high error rates. Pfizer has successfully implemented LabVantage Micro/EM™, powered by MODA™ by Lonza. As a result, Pfizer is achieving their goal to automate their QC processes and regulatory compliance across some of their global manufacturing facilities.
In May 2010, MODA became a Lonza company. What started as a company-wide initiative to eliminate waste, reduce lead and labor time, and improve overall compliance, inspired a robust informatics platform for the life sciences industry.
About MODA™ Solution
More science. Less paper.™ The MODA™ product strengthens Lonza’s Rapid Testing Solutions platform by adding a complementary product offering for quality assurance (QA) and quality control (QC) organizations in the life science industry. The MODA™ solution offers automated data collection, on demand analytics and workflow visualization of regulated manufacturing processes, including environmental monitoring, utility testing, and product testing. The MODA™ mobile data acquisition platform eliminates inefficiencies and reduces error rates inherent with paper-based systems in regulated manufacturing operations. Further information can be found at http://www.lonza.com/moda
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, the company had sales of CHF 2.690 billion. Further information can be found at http://www.lonza.com.
| For media enquiries, please contact: | ||
|
No comments:
Post a Comment